Regeneron reports 84-week Phase III data for Pasatru in adult FOP
Regeneron Pharmaceuticals has reported 84-week findings from the Phase III OPTIMA trial assessing Pasatru in adults with FOP.
The post Regeneron reports 84-week Phase III data for Pasatru in adult FOP appeared first on Clinical Trials Arena .